An argument can be made for engineering a malaria vaccine to preferentially induce IgG3 antibodies that have been associated with antibody-dependent cellular inhibition of parasite growth (15) and associated with the acquisition of clinical immunity (16). Here, IGHG3 is linked to malaria.